Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases
Deep Apple Therapeutics, Inc. announced a research collaboration and exclusive worldwide license agreement with Novo Nordisk to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for …